BTIG Reiterates Buy on Humacyte, Maintains $2 Price Target
Humacyte Inc HUMA
$0.65
▼ -2.71%
($-0.02)
🎢 High Beta
🗓️ Earnings Next Week
Open
$0.69
Prev Close
$0.67
Day Range
$0.64 – $0.69
52W Range
$0.55 – $2.76
Market Cap
$176.18M
Beta
2.56
EPS (TTM)
$-0.57
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-09-22 |
| Shares Out. | 269,640,000 |
| Website | humacyte.com/ ↗ |
| Phone | 13026587581 |
| Employees | 184 |
| Revenue | $495,000 |
| Gross Profit | -$1.5M |
| Net Income | -$17.6M |
| Free Cash Flow | -$102.4M |
| Total Assets | $110.6M |
| Total Liabilities | $98.9M |
| Equity | $11.6M |
About Humacyte Inc
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Humacyte Inc is a publicly traded company under the ticker symbol HUMA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-07-01)